Item 7.01. Regulation FD Disclosure

On January 25, 2023, Aytu BioPharma, Inc. (the "Company") issued a press release titled "Aytu BioPharma Regains Nasdaq Bid Price Compliance."

A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 and the exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, or incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.




Item 8.01.  Other Events

On January 23, 2023, the Company received notification from the staff (the "Staff") of The Nasdaq Stock Market ("Nasdaq") that the Company regained compliance with Listing Rule 5550(a)(2) (the "Rule"), which requires a minimum bid price of $1.00 per share. The Staff notified the Company that it has regained compliance with the Rule and it has closed the matter. The Company is now fully compliant with all Nasdaq listing rules.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits



Exhibit    Description
99.1         Press release dated January 25, 2023
104        Cover Page Interactive Data File (formatted as inline XBRL)

© Edgar Online, source Glimpses